Literature DB >> 2936772

Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study.

W R Gammon, C Meyer, S Lantis, P Shenefelt, G Reizner, D J Cripps.   

Abstract

The efficacy of erythromycin base (E-Mycin tablets, 333 mg) and the efficacy of tetracycline hydrochloride (Panmycin tablets) were compared in this double-blind, randomized study. Two hundred patients with moderate to moderately severe acne vulgaris were randomly assigned to the study. One hundred patients received 1 gm of erythromycin base by mouth per day for 4 weeks, followed by 333 mg/day for 8 weeks, plus placebo for tetracycline. The second group of patients received 1 gm of tetracycline by mouth per day for 4 weeks, followed by 500 mg/day for 8 weeks, plus placebo for erythromycin. Both drugs reduced acne severity to the same extent. Pustules, papules, and open comedo counts decreased significantly over the 12-week period. Seventy-seven percent of the erythromycin-treated patients and 89% of the tetracycline-treated patients stated that their acne was markedly improved or improved by week 12. Most of the side effects in patients treated with erythromycin were gastrointestinal symptoms. Among the side effects in patients treated with tetracycline were Candida vaginitis in one patient and pseudotumor cerebri in one patient.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936772     DOI: 10.1016/s0190-9622(86)70019-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  A Family Physician's Approach to the Treatment of Acne.

Authors:  N R Rockerbie
Journal:  Can Fam Physician       Date:  1988-12       Impact factor: 3.275

Review 2.  Acneiform facial eruptions: a problem for young women.

Authors:  Melody J Cheung; Muba Taher; Gilles J Lauzon
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

3.  [Acne vulgaris].

Authors:  M Toscano; J Tousignant; G Panet-Raymond
Journal:  Can Fam Physician       Date:  1992-11       Impact factor: 3.275

4.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

Review 5.  Acne vulgaris.

Authors:  Sarah Purdy; David Deberker
Journal:  BMJ Clin Evid       Date:  2008-05-15

6.  Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

Authors:  Aminah Jatoi; Kendrith Rowland; Jeff A Sloan; Howard M Gross; Paul A Fishkin; Stephen P Kahanic; Paul J Novotny; Paul L Schaefer; David B Johnson; Loren K Tschetter; Charles L Loprinzi
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

Review 7.  Acne vulgaris.

Authors:  Sarah Purdy; David de Berker
Journal:  BMJ Clin Evid       Date:  2011-01-05

8.  Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.

Authors:  Thomas C Wehler; Claudine Graf; Markus Möhler; Jutta Herzog; Martin R Berger; Ines Gockel; Hauke Lang; Matthias Theobald; Peter R Galle; Carl C Schimanski
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-07       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.